@entity2590 are clonal stem cell disorders, and allogeneic hemopoietic cell transplantation (HCT) is the only therapy with curative potential. Among @entity1 with less-advanced @entity2590 , 3-year survivals of 65% to 75% are achievable with human leukocyte antigen (HLA)-identical related and HLA-matched unrelated donors. The probability of relapse is less than 5%. Among @entity1 with @entity1442 (> or = 5% marrow blasts), 35% to 45% and 25% to 30%, respectively, are surviving in remission after transplantation from related or unrelated donors. The incidence of post-transplant relapse is 10% to 35%. Criteria of the International Prognostic Scoring System, originally developed for nontransplanted @entity1 , also predict relapse and survival after HCT. Refined conditioning regimens have permitted successful HCT even in @entity1 in their seventh decade of life. Results with a regimen using a combination of @entity1863 (targeted to predetermined plasma levels) and @entity786 are particularly encouraging. Improved survival with transplants from unrelated volunteer donors reflects selection of donors on the basis of high-resolution (allele-level) HLA typing. Nevertheless, transplant-related morbidity and mortality, including @entity2132 , remain challenges that need to be addressed with innovative approaches. Some @entity1 who achieve a chemotherapy-induced complete remission may also benefit from autologous HCT.

Hemopoietic cell transplantation for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndromes', 'Myelodysplastic syndromes'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['graft-versus-host disease'] @entity1863 :: ('MESH:D002066', 'Chemical') :: ['busulfan']
@entity2590 :: (MESH:D009190,Disease) :: ['myelodysplastic syndromes']
